Idorsia and SPV investors back aprocitentan launch with CHF 120m
Idorsia has announced a proposed commercialisation partnership with noteholders in its special-purpose vehicle, Idorsia Investments SARL, to fund the speciality launch of aprocitentan, sold as TRYVIO in the United States and JERAYGO in Europe. The structure combines CHF 72 million from participating SPV noteholders, issued as new notes, with CHF 48 million that Idorsia itself will contribute over two years, bringing the total dedicated launch capital to CHF 120 million.
In return, Idorsia receives a 30% share of global net revenues from aprocitentan from the effective date of the agreement, plus 88% of the residual upside value of the three SPV assets once the notes are fully repaid. The noteholders receive a 12% earn-out across the three assets once the debt is cleared. Noteholder approval and final documentation are expected before the end of 2026.
The drug and its market
Aprocitentan is an oral, once-daily dual endothelin receptor antagonist (ERA), the first in its class to be approved for systemic hypertension. It works by blocking the binding of endothelin-1 to both ETA and ETB receptors, a mechanism entirely distinct from the renin-angiotensin-aldosterone system (RAAS) pathway that underpins most existing antihypertensive therapies. TRYVIO has been commercially available in the US since October 2024 and is now included in the American College of Cardiology and American Heart Association guidelines for high blood pressure management.
Resistant or difficult-to-control hypertension, where blood pressure remains above target despite treatment with multiple agents, represents a substantial and underserved patient population. Idorsia's clinical data showed sustained double-digit blood pressure reductions in patients uncontrolled on existing medicines, including those with chronic kidney disease. The drug's tolerability profile is notable for the absence of hyperkalemia, hyponatremia, and hypotension, side effects commonly associated with add-on therapies in this setting.
Chief medical officer Amer Joseph highlighted the unmet need directly: "Having personally treated many patients at a leading hypertension centre, I've seen firsthand the limitations of existing treatments focused on inhibiting the RAAS pathway. Aprocitentan, through its unique and novel mechanism targeting the endothelin pathway, offers a much-needed treatment option to these patients."
Competitive landscape and commercial path
The resistant hypertension space has historically attracted limited late-stage pharmaceutical attention, partly because of the complexity of demonstrating efficacy in a polypharmacy population. Aprocitentan's distinct mechanism gives it a credible differentiation story, though the commercial track record since the October 2024 US launch has yet to be detailed publicly by Idorsia. The company's business plan projects breakeven in 2029, which implies a multi-year investment phase ahead.
Idorsia's go-to-market strategy focuses initially on hypertension centres, nephrologists, and cardiometabolic specialists rather than primary care, a narrower and more capital-efficient approach than a broad launch. The company says it will add co-promotion partnerships and pursue licensing deals in additional territories as market access broadens. European and Canadian commercialisation will proceed on a phased basis alongside the US effort.
The SPV structure is notable from a corporate finance perspective. Idorsia has been operating under financial pressure since divesting daridorexant (QUVIVIQ) and restructuring; this arrangement allows it to share launch risk and reward with existing creditors rather than raise fresh equity. Investors will be watching early prescription data and reimbursement progress in the US closely, as these will determine whether the 2029 breakeven projection is realistic and whether the endothelin pathway can establish itself as a meaningful fourth pillar in hypertension management.